RxDoctor Payments Data

Andrew Zazaian, DO

Internal Medicine · Waterford, MINPI 1982692273

Payments from drug & device makers

$1,301in general payments, 2019–2025

Across 48 payments — averaging $27.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$313
  • Pfizer$165
  • E.r. Squibb & Sons, L.L.C.$153
  • Boehringer Ingelheim$121
  • Sanofi$114
  • AbbVie$95
  • plus $340 from 8 others

What the payments were for

  • Food & beverage$1,301100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,301 in reported general payments places this provider in the 75th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$165,972
Medicare patients
574
Services billed
1,711

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban66$59,629
JanuviaSitagliptin Phosphate41$52,992
JardianceEmpagliflozin45$49,272
OzempicSemaglutide48$44,312
Trelegy ElliptaFluticasone/Umeclidin/Vilanter46$35,643
XareltoRivaroxaban16$23,687
TrulicityDulaglutide25$23,429
FarxigaDapagliflozin Propanediol11$14,730
MounjaroTirzepatide13$13,034
Lantus SolostarInsulin Glargine,hum.Rec.Anlog53$10,307
JanumetSitagliptin Phos/Metformin Hcl12$9,096
BrilintaTicagrelor14$8,855
InvokanaCanagliflozin12$6,904
Spiriva HandihalerTiotropium Bromide12$5,905
Atorvastatin Calcium316$4,212

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$165$59,62966 claims
Boehringer IngelheimJardiance$121$49,27245 claims
Lilly USA, LLCTrulicity, Mounjaro$78$36,46238 claims
GSKTrelegy Ellipta$313$35,64346 claims
Johnson & JohnsonXarelto, Invokana$34$30,59128 claims
AstraZenecaFarxiga, Brilinta$19$23,58425 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Waterford

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →